Ultragenyx Pharmaceutical (RARE) Return on Equity (2016 - 2025)
Ultragenyx Pharmaceutical (RARE) has disclosed Return on Equity for 10 consecutive years, with 16.23% as the latest value for Q4 2025.
- On a quarterly basis, Return on Equity rose 1813.0% to 16.23% in Q4 2025 year-over-year; TTM through Dec 2025 was 16.23%, a 1813.0% increase, with the full-year FY2025 number at 6.57%, down 442.0% from a year prior.
- Return on Equity was 16.23% for Q4 2025 at Ultragenyx Pharmaceutical, up from 7.24% in the prior quarter.
- In the past five years, Return on Equity ranged from a high of 16.23% in Q4 2025 to a low of 7.9% in Q3 2023.
- A 5-year average of 1.49% and a median of 1.81% in 2022 define the central range for Return on Equity.
- Peak YoY movement for Return on Equity: crashed -672bps in 2023, then soared 1813bps in 2025.
- Ultragenyx Pharmaceutical's Return on Equity stood at 0.49% in 2021, then crashed by -251bps to 1.72% in 2022, then plummeted by -130bps to 3.96% in 2023, then surged by 52bps to 1.89% in 2024, then skyrocketed by 957bps to 16.23% in 2025.
- Per Business Quant, the three most recent readings for RARE's Return on Equity are 16.23% (Q4 2025), 7.24% (Q3 2025), and 3.61% (Q2 2025).